Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T77913
(Former ID: TTDS00086)
|
|||||
| Target Name |
Histamine H1 receptor (H1R)
|
|||||
| Synonyms |
HH1R; H1R
Click to Show/Hide
|
|||||
| Gene Name |
HRH1
|
|||||
| Target Type |
Successful target
|
[1] | ||||
| Disease | [+] 17 Target-related Diseases | + | ||||
| 1 | Allergic/hypersensitivity disorder [ICD-11: 4A80-4A8Z] | |||||
| 2 | Anxiety disorder [ICD-11: 6B00-6B0Z] | |||||
| 3 | Breathing abnormality [ICD-11: MD11] | |||||
| 4 | Conjunctiva disorder [ICD-11: 9A60] | |||||
| 5 | Cough [ICD-11: MD12] | |||||
| 6 | Depression [ICD-11: 6A70-6A7Z] | |||||
| 7 | Episodic vestibular syndrome [ICD-11: AB31] | |||||
| 8 | Headache [ICD-11: 8A80-8A84] | |||||
| 9 | Insomnia [ICD-11: 7A00-7A0Z] | |||||
| 10 | Morning sickness disorder [ICD-11: SC00] | |||||
| 11 | Nasopharyngitis [ICD-11: CA00] | |||||
| 12 | Nausea/vomiting [ICD-11: MD90] | |||||
| 13 | Parkinsonism [ICD-11: 8A00] | |||||
| 14 | Pruritus [ICD-11: EC90] | |||||
| 15 | Rheumatoid arthritis [ICD-11: FA20] | |||||
| 16 | Sleep-wake disorder [ICD-11: 7A00-7B2Z] | |||||
| 17 | Vasomotor/allergic rhinitis [ICD-11: CA08] | |||||
| Function |
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Click to Show/Hide
|
|||||
| BioChemical Class |
GPCR rhodopsin
|
|||||
| UniProt ID | ||||||
| Sequence |
MSLPNSSCLLEDKMCEGNKTTMASPQLMPLVVVLSTICLVTVGLNLLVLYAVRSERKLHT
VGNLYIVSLSVADLIVGAVVMPMNILYLLMSKWSLGRPLCLFWLSMDYVASTASIFSVFI LCIDRYRSVQQPLRYLKYRTKTRASATILGAWFLSFLWVIPILGWNHFMQQTSVRREDKC ETDFYDVTWFKVMTAIINFYLPTLLMLWFYAKIYKAVRQHCQHRELINRSLPSFSEIKLR PENPKGDAKKPGKESPWEVLKRKPKDAGGGSVLKSPSQTPKEMKSPVVFSQEDDREVDKL YCFPLDIVHMQAAAEGSSRDYVAVNRSHGQLKTDEQGLNTHGASEISEDQMLGDSQSFSR TDSDTTTETAPGKGKLRSGSNTGLDYIKFTWKRLRSHSRQYVSGLHMNRERKAAKQLGFI MAAFILCWIPYFIFFMVIAFCKNCCNEHLHMFTIWLGYINSTLNPLIYPLCNENFKKTFK RILHIRS Click to Show/Hide
|
|||||
| 3D Structure | Click to Show 3D Structure of This Target | AlphaFold | ||||
| ADReCS ID | BADD_A00273 ; BADD_A02979 ; BADD_A04075 | |||||
| HIT2.0 ID | T06N1B | |||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Approved Drug(s) | [+] 46 Approved Drugs | + | ||||
| 1 | Aceprometazine | Drug Info | Approved | Sleep-wake disorder | [16] | |
| 2 | Acrivastine | Drug Info | Approved | Allergic rhinitis | [17] | |
| 3 | Alcaftadine | Drug Info | Approved | Allergic conjunctivitis | [18], [19] | |
| 4 | Antazoline | Drug Info | Approved | Nasal congestion | [20], [21] | |
| 5 | Azatadine | Drug Info | Approved | Allergic rhinitis | [22], [23] | |
| 6 | Azelastine | Drug Info | Approved | Allergic conjunctivitis | [24], [3] | |
| 7 | Brompheniramine | Drug Info | Approved | Allergic rhinitis | [25], [26] | |
| 8 | Buclizine | Drug Info | Approved | Nausea | [27], [28] | |
| 9 | Carbinoxamine | Drug Info | Approved | Vasomotor/allergic rhinitis | [14] | |
| 10 | Cetirizine | Drug Info | Approved | Allergic rhinitis | [29], [17] | |
| 11 | Chlophedianol | Drug Info | Approved | Dry cough | [14] | |
| 12 | Chlorpheniramine | Drug Info | Approved | Allergic rhinitis | [30], [31] | |
| 13 | Cinnarizine | Drug Info | Approved | Vertigo meniere disease | [32] | |
| 14 | Clemastine | Drug Info | Approved | Allergic rhinitis | [33], [34] | |
| 15 | Cyclizine | Drug Info | Approved | Nausea | [35], [36] | |
| 16 | Cyproheptadine | Drug Info | Approved | Rhinitis | [14] | |
| 17 | Desloratadine | Drug Info | Approved | Allergic rhinitis | [37], [38] | |
| 18 | Dexbrompheniramine | Drug Info | Approved | Hay fever | [14], [39], [40] | |
| 19 | Dexchlorpheniramine Maleate | Drug Info | Approved | Rhinitis | [14] | |
| 20 | Dimethindene | Drug Info | Approved | Respiratory allergy | [15], [14] | |
| 21 | Diphenhydramine | Drug Info | Approved | Meniere disease | [14] | |
| 22 | Doxepin | Drug Info | Approved | Depression | [41], [42] | |
| 23 | Emedastine | Drug Info | Approved | Allergic conjunctivitis | [43], [3] | |
| 24 | Epinastine | Drug Info | Approved | Allergic conjunctivitis | [44], [3] | |
| 25 | Ergotidine | Drug Info | Approved | Respiratory allergy | [14], [45], [46] | |
| 26 | Ethopropazine | Drug Info | Approved | Parkinson disease | [47], [48] | |
| 27 | Fexofenadine | Drug Info | Approved | Allergic rhinitis | [49], [17] | |
| 28 | Hydroxyzine | Drug Info | Approved | Anxiety disorder | [50], [51] | |
| 29 | Levocabastine | Drug Info | Approved | Allergic conjunctivitis | [52], [3] | |
| 30 | Levocetirizine dihydrochloride | Drug Info | Approved | Allergic rhinitis | [53], [54] | |
| 31 | Loratadine | Drug Info | Approved | Allergy | [55], [38] | |
| 32 | Mepyramine | Drug Info | Approved | Allergy | [56], [57] | |
| 33 | Mepyramine maleate | Drug Info | Approved | Headache | [58], [59] | |
| 34 | Mequitazine | Drug Info | Approved | Allergic rhinitis | [60] | |
| 35 | Methdilazine | Drug Info | Approved | Allergic rhinitis | [61], [62] | |
| 36 | Mizolastine | Drug Info | Approved | Allergic rhinitis | [63] | |
| 37 | Olopatadine | Drug Info | Approved | Allergic conjunctivitis | [64], [3] | |
| 38 | Oxatomide | Drug Info | Approved | Hay fever | [58] | |
| 39 | Pemirolast | Drug Info | Approved | Allergic conjunctivitis | [3], [14], [65] | |
| 40 | Phenindamine | Drug Info | Approved | Common cold | [66] | |
| 41 | Pheniramine | Drug Info | Approved | Hay fever | [67], [3] | |
| 42 | Propiomazine | Drug Info | Approved | Insomnia | [14], [68], [69] | |
| 43 | Tranilast | Drug Info | Approved | Ocular allergy | [70], [3] | |
| 44 | Trimeprazine | Drug Info | Approved | Allergic rhinitis | [71], [72] | |
| 45 | Tripelennamine | Drug Info | Approved | Hypersensitivity | [14] | |
| 46 | Triprolidine | Drug Info | Approved | Hay fever | [73], [74] | |
| Clinical Trial Drug(s) | [+] 9 Clinical Trial Drugs | + | ||||
| 1 | AC-170 | Drug Info | Phase 3 | Allergic conjunctivitis | [75] | |
| 2 | Carebastine | Drug Info | Phase 3 | Ocular allergy | [3] | |
| 3 | E-4716 | Drug Info | Phase 2 | Respiratory disease | [76] | |
| 4 | LY-2624803 | Drug Info | Phase 2 | Insomnia | [77] | |
| 5 | Noberastine | Drug Info | Phase 2 | Asthma | [78] | |
| 6 | OBE-101 | Drug Info | Phase 2 | Obesity | [79] | |
| 7 | RP5063 | Drug Info | Phase 2 | Schizophrenia | [80] | |
| 8 | UCB-35440 | Drug Info | Phase 2 | Rhinitis | [81] | |
| 9 | Vapitadine | Drug Info | Phase 2 | Allergic skin disorder | [82] | |
| Discontinued Drug(s) | [+] 9 Discontinued Drugs | + | ||||
| 1 | Terfenadine | Drug Info | Withdrawn from market | Allergy | [84], [17] | |
| 2 | GSK835726 | Drug Info | Discontinued in Phase 2 | Allergic rhinitis | [85] | |
| 3 | HSR-609 | Drug Info | Discontinued in Phase 2 | Rhinitis | [86] | |
| 4 | Mequitamium iodide | Drug Info | Discontinued in Phase 2 | Asthma | [87] | |
| 5 | ReN-1869 | Drug Info | Discontinued in Phase 2 | Pain | [88] | |
| 6 | SUN-1334H | Drug Info | Discontinued in Phase 2 | Allergic rhinitis | [89] | |
| 7 | AZD-1744 | Drug Info | Discontinued in Phase 1 | Asthma | [90] | |
| 8 | GSK1004723 | Drug Info | Discontinued in Phase 1 | Allergic rhinitis | [91] | |
| 9 | Selenotifen | Drug Info | Terminated | Asthma | [93] | |
| Mode of Action | [+] 5 Modes of Action | + | ||||
| Antagonist | [+] 60 Antagonist drugs | + | ||||
| 1 | Aceprometazine | Drug Info | [94] | |||
| 2 | Acrivastine | Drug Info | [95], [96] | |||
| 3 | Alcaftadine | Drug Info | [19] | |||
| 4 | Antazoline | Drug Info | [96], [97], [98], [99] | |||
| 5 | Azatadine | Drug Info | [100] | |||
| 6 | Azelastine | Drug Info | [58], [101] | |||
| 7 | Brompheniramine | Drug Info | [102] | |||
| 8 | Buclizine | Drug Info | [103] | |||
| 9 | Carbinoxamine | Drug Info | [104] | |||
| 10 | Cetirizine | Drug Info | [105], [106] | |||
| 11 | Chlophedianol | Drug Info | [107] | |||
| 12 | Chlorpheniramine | Drug Info | [58], [108], [59] | |||
| 13 | Cinnarizine | Drug Info | [109], [110] | |||
| 14 | Clemastine | Drug Info | [1], [111] | |||
| 15 | Cyclizine | Drug Info | [112], [113], [114] | |||
| 16 | Cyproheptadine | Drug Info | [115], [116] | |||
| 17 | Desloratadine | Drug Info | [117], [118] | |||
| 18 | Dexbrompheniramine | Drug Info | [119] | |||
| 19 | Dimethindene | Drug Info | [15], [59], [121], [122] | |||
| 20 | Diphenhydramine | Drug Info | [58], [123] | |||
| 21 | Emedastine | Drug Info | [126] | |||
| 22 | Epinastine | Drug Info | [127] | |||
| 23 | Fexofenadine | Drug Info | [118], [106] | |||
| 24 | Hydroxyzine | Drug Info | [128], [129] | |||
| 25 | Levocabastine | Drug Info | [130], [131] | |||
| 26 | Levocetirizine dihydrochloride | Drug Info | [118], [58], [132] | |||
| 27 | Loratadine | Drug Info | [133], [134], [135] | |||
| 28 | Mepyramine | Drug Info | [57], [136], [105] | |||
| 29 | Mepyramine maleate | Drug Info | [57], [58], [59], [105], [136] | |||
| 30 | Mequitazine | Drug Info | [137] | |||
| 31 | Methdilazine | Drug Info | [138] | |||
| 32 | Mizolastine | Drug Info | [139] | |||
| 33 | Olopatadine | Drug Info | [3] | |||
| 34 | Oxatomide | Drug Info | [58], [131] | |||
| 35 | Pemirolast | Drug Info | [140] | |||
| 36 | Phenindamine | Drug Info | [141] | |||
| 37 | Pheniramine | Drug Info | [142] | |||
| 38 | Propiomazine | Drug Info | [143] | |||
| 39 | Tranilast | Drug Info | [3] | |||
| 40 | Trimeprazine | Drug Info | [144] | |||
| 41 | Tripelennamine | Drug Info | [145], [146], [147], [148] | |||
| 42 | Triprolidine | Drug Info | [149] | |||
| 43 | AC-170 | Drug Info | [151] | |||
| 44 | Carebastine | Drug Info | [3] | |||
| 45 | Noberastine | Drug Info | [153] | |||
| 46 | Vapitadine | Drug Info | [157] | |||
| 47 | Terfenadine | Drug Info | [159], [134] | |||
| 48 | GSK835726 | Drug Info | [161] | |||
| 49 | HSR-609 | Drug Info | [162], [14] | |||
| 50 | ReN-1869 | Drug Info | [164] | |||
| 51 | SUN-1334H | Drug Info | [165] | |||
| 52 | GSK1004723 | Drug Info | [161] | |||
| 53 | (+)-cis-H2-PAT | Drug Info | [168] | |||
| 54 | (+)-trans-H2-PAT | Drug Info | [168] | |||
| 55 | (+/-)-cis-H2-PAT | Drug Info | [168] | |||
| 56 | (-)-trans-H2-PAT | Drug Info | [168] | |||
| 57 | arpromidine | Drug Info | [171] | |||
| 58 | BU-E 47 | Drug Info | [171] | |||
| 59 | Hydroxyclemastine | Drug Info | [1], [111] | |||
| 60 | impromidine | Drug Info | [178] | |||
| Modulator | [+] 10 Modulator drugs | + | ||||
| 1 | Dexchlorpheniramine Maleate | Drug Info | [120] | |||
| 2 | Ethopropazine | Drug Info | [120] | |||
| 3 | E-4716 | Drug Info | [76] | |||
| 4 | LY-2624803 | Drug Info | [152] | |||
| 5 | OBE-101 | Drug Info | [154] | |||
| 6 | UCB-35440 | Drug Info | [156] | |||
| 7 | Norastemizole | Drug Info | [160] | |||
| 8 | Mequitamium iodide | Drug Info | [163] | |||
| 9 | AZD-1744 | Drug Info | [166] | |||
| 10 | Selenotifen | Drug Info | [167] | |||
| Inhibitor | [+] 26 Inhibitor drugs | + | ||||
| 1 | Doxepin | Drug Info | [124], [125] | |||
| 2 | RUPATADINE | Drug Info | [150] | |||
| 3 | Citalopram derivative 1 | Drug Info | [158] | |||
| 4 | 1-(4-p-Tolyl-butyl)-piperidine | Drug Info | [169] | |||
| 5 | 1-[(Furan-2(5H)-one)-4-methyl]-desloratadine | Drug Info | [170] | |||
| 6 | 2-(9,10-dihydroanthracen-9-yl)-N-methylethanamine | Drug Info | [172] | |||
| 7 | 3,3-diphenylpropan-1-amine | Drug Info | [172] | |||
| 8 | 4,4-Diphenylbutan-1-amine | Drug Info | [172] | |||
| 9 | 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one | Drug Info | [174] | |||
| 10 | 9-(2-aminoethyl)-9,10-dihydroanthracene | Drug Info | [172] | |||
| 11 | 9-(2-aminopropyl)-9,10-dihydroanthracene | Drug Info | [172] | |||
| 12 | 9-(Aminomethyl)-9,10-dihydroanthracene | Drug Info | [172] | |||
| 13 | 9-Phenyl-2,3-dihydro-1H-indeno[2,1-c]pyridine | Drug Info | [175] | |||
| 14 | DIMEBOLIN | Drug Info | [176] | |||
| 15 | Diphenyl(piperidin-4-yl)methanol | Drug Info | [169] | |||
| 16 | KF-A6 | Drug Info | [179] | |||
| 17 | MDL-28163 | Drug Info | [150] | |||
| 18 | N,N-dimethyl-2,2-diphenylethanamine | Drug Info | [172] | |||
| 19 | N,N-Dimethyl-3,3-diphenylpropan-1-amine | Drug Info | [172] | |||
| 20 | N,N-dimethyl-4,4-diphenylbutan-1-amine | Drug Info | [172] | |||
| 21 | N-methyl-3,3-diphenylpropan-1-amine | Drug Info | [172] | |||
| 22 | N-methyl-4,4-diphenylbutan-1-amine | Drug Info | [172] | |||
| 23 | OCTOCLOTHEPIN | Drug Info | [180] | |||
| 24 | R-226161 | Drug Info | [181] | |||
| 25 | R-dimethindene | Drug Info | [182] | |||
| 26 | VUF-10148 | Drug Info | [183] | |||
| Agonist | [+] 11 Agonist drugs | + | ||||
| 1 | Ergotidine | Drug Info | [46] | |||
| 2 | 2-(3-bromophenyl)histamine | Drug Info | [171] | |||
| 3 | 2-(3-chlorophenyl)histamine | Drug Info | [171] | |||
| 4 | 2-(3-iodophenyl)histamine | Drug Info | [171] | |||
| 5 | 2-pyridylethylamine | Drug Info | [173] | |||
| 6 | dimethylhistaprodifen | Drug Info | [171] | |||
| 7 | histaprodifen | Drug Info | [177] | |||
| 8 | methylhistaprodifen | Drug Info | [171] | |||
| 9 | oxo-arpromidine | Drug Info | [178] | |||
| 10 | UR-PG131A | Drug Info | [178] | |||
| 11 | UR-PG146 | Drug Info | [178] | |||
| Partial agonist | [+] 1 Partial agonist drugs | + | ||||
| 1 | RP5063 | Drug Info | [155] | |||
| Cell-based Target Expression Variations | Top | |||||
|---|---|---|---|---|---|---|
| Cell-based Target Expression Variations | ||||||
| Drug Binding Sites of Target | Top | |||||
|---|---|---|---|---|---|---|
| Ligand Name: Ergotidine | Ligand Info | |||||
| Structure Description | Cryo-EM structure of histamine H1 receptor Gq complex | PDB:7DFL | ||||
| Method | Electron microscopy | Resolution | 3.30 Å | Mutation | No | [184] |
| PDB Sequence |
MPLVVVLSTI
37 CLVTVGLNLL47 VLYAVRSERK57 LHTVGNLYIV67 SLSVADLIVG77 AVVMPMNILY 87 LLMSKWSLGR97 PLCLFWLSMD107 YVASTASIFS117 VFILCIDRYR127 SVQQPLRYLK 137 YRTKTRASAT147 ILGAWFLSFL157 WVIPILGWNH167 FMQQTSVRRE177 DKCETDFYDV 187 TWFKVMTAII197 NFYLPTLLML207 WFYAKIYKAV217 RQHCLHMNRE410 RKAAKQLGFI 420 MAAFILCWIP430 YFIFFMVIAF440 CKNCCNEHLH450 MFTIWLGYIN460 STLNPLIYPL 470 CNENFKKTFK480 RILHI
|
|||||
|
|
||||||
| Ligand Name: Doxepin | Ligand Info | |||||
| Structure Description | Structure of the human histamine H1 receptor in complex with doxepin | PDB:3RZE | ||||
| Method | X-ray diffraction | Resolution | 3.10 Å | Mutation | Yes | [185] |
| PDB Sequence |
MPLVVVLSTI
37 CLVTVGLNLL47 VLYAVRSERK57 LHTVGNLYIV67 SLSVADLIVG77 AVVMPMNILY 87 LLMSKWSLGR97 PLCLFWLSMD107 YVASTASIFS117 VFILCIDRYR127 SVQQPLRYLK 137 YRTKTRASAT147 ILGAWFLSFL157 WVIPILGWNH167 RREDKCETDF184 YDVTWFKVMT 194 AIINFYLPTL204 LMLWFYAKIY214 KAVRQHCNIF1004 EMLRIDEGLR1014 LKIYKDTEGY 1024 YTIGIGHLLT1034 KSPSLNAAKS1044 ELDKAIGRNT1054 NGVITKDEAE1064 KLFNQDVDAA 1074 VRGILRNAKL1084 KPVYDSLDAV1094 RRAALINMVF1104 QMGETGVAGF1114 TNSLRMLQQK 1124 RWDEAAVNLA1134 KSRWYNQTPN1144 RAKRVITTFR1154 TGTWDAYLHM407 NRERKAAKQL 417 GFIMAAFILC427 WIPYFIFFMV437 IAFCKNCCNE447 HLHMFTIWLG457 YINSTLNPLI 467 YPLCNENFKK477 TFKRILHI
|
|||||
|
|
||||||
| Click to View More Binding Site Information of This Target with Different Ligands | ||||||
| Different Human System Profiles of Target | Top |
|---|---|
|
Human Similarity Proteins
of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.
A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs
(Brief Bioinform, 21: 649-662, 2020).
Human Tissue Distribution
of target is determined from a proteomics study that quantified more than 12,000 genes across 32 normal human tissues. Tissue Specificity (TS) score was used to define the enrichment of target across tissues.
The distribution of targets among different tissues or organs need to be taken into consideration when assessing the target druggability, as it is generally accepted that the wider the target distribution, the greater the concern over potential adverse effects
(Nat Rev Drug Discov, 20: 64-81, 2021).
Human Pathway Affiliation
of target is determined by the life-essential pathways provided on KEGG database. The target-affiliated pathways were defined based on the following two criteria (a) the pathways of the studied target should be life-essential for both healthy individuals and patients, and (b) the studied target should occupy an upstream position in the pathways and therefore had the ability to regulate biological function.
Targets involved in a fewer pathways have greater likelihood to be successfully developed, while those associated with more human pathways increase the chance of undesirable interferences with other human processes
(Pharmacol Rev, 58: 259-279, 2006).
Biological Network Descriptors
of target is determined based on a human protein-protein interactions (PPI) network consisting of 9,309 proteins and 52,713 PPIs, which were with a high confidence score of ≥ 0.95 collected from STRING database.
The network properties of targets based on protein-protein interactions (PPIs) have been widely adopted for the assessment of target’s druggability. Proteins with high node degree tend to have a high impact on network function through multiple interactions, while proteins with high betweenness centrality are regarded to be central for communication in interaction networks and regulate the flow of signaling information
(Front Pharmacol, 9, 1245, 2018;
Curr Opin Struct Biol. 44:134-142, 2017).
Human Similarity Proteins
Human Tissue Distribution
Human Pathway Affiliation
Biological Network Descriptors
|
|
|
Note:
If a protein has TS (tissue specficity) scores at least in one tissue >= 2.5, this protein is called tissue-enriched (including tissue-enriched-but-not-specific and tissue-specific). In the plots, the vertical lines are at thresholds 2.5 and 4.
|
| KEGG Pathway | Pathway ID | Affiliated Target | Pathway Map |
|---|---|---|---|
| Calcium signaling pathway | hsa04020 | Affiliated Target |
|
| Class: Environmental Information Processing => Signal transduction | Pathway Hierarchy | ||
| Neuroactive ligand-receptor interaction | hsa04080 | Affiliated Target |
|
| Class: Environmental Information Processing => Signaling molecules and interaction | Pathway Hierarchy | ||
| Inflammatory mediator regulation of TRP channels | hsa04750 | Affiliated Target |
|
| Class: Organismal Systems => Sensory system | Pathway Hierarchy | ||
| Degree | 1 | Degree centrality | 1.07E-04 | Betweenness centrality | 0.00E+00 |
|---|---|---|---|---|---|
| Closeness centrality | 1.86E-01 | Radiality | 1.31E+01 | Clustering coefficient | 0.00E+00 |
| Neighborhood connectivity | 5.20E+01 | Topological coefficient | 1.00E+00 | Eccentricity | 12 |
| Download | Click to Download the Full PPI Network of This Target | ||||
| Chemical Structure based Activity Landscape of Target | Top |
|---|---|
| Drug Property Profile of Target | Top | |
|---|---|---|
| (1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
|
||
| (3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
|
||
| (5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
|
||
| "RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five | ||
| Co-Targets | Top | |||||
|---|---|---|---|---|---|---|
| Co-Targets | ||||||
| Target Poor or Non Binders | Top | |||||
|---|---|---|---|---|---|---|
| Target Poor or Non Binders | ||||||
| Target Regulators | Top | |||||
|---|---|---|---|---|---|---|
| Target-regulating microRNAs | ||||||
| Target Profiles in Patients | Top | |||||
|---|---|---|---|---|---|---|
| Target Expression Profile (TEP) | ||||||
| Target Affiliated Biological Pathways | Top | |||||
|---|---|---|---|---|---|---|
| KEGG Pathway | [+] 3 KEGG Pathways | + | ||||
| 1 | Calcium signaling pathway | |||||
| 2 | Neuroactive ligand-receptor interaction | |||||
| 3 | Inflammatory mediator regulation of TRP channels | |||||
| Panther Pathway | [+] 1 Panther Pathways | + | ||||
| 1 | Histamine H1 receptor mediated signaling pathway | |||||
| Reactome | [+] 2 Reactome Pathways | + | ||||
| 1 | Histamine receptors | |||||
| 2 | G alpha (q) signalling events | |||||
| WikiPathways | [+] 6 WikiPathways | + | ||||
| 1 | Monoamine GPCRs | |||||
| 2 | GPCRs, Class A Rhodopsin-like | |||||
| 3 | IL-4 Signaling Pathway | |||||
| 4 | Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| 5 | GPCR ligand binding | |||||
| 6 | GPCR downstream signaling | |||||
| Target-Related Models and Studies | Top | |||||
|---|---|---|---|---|---|---|
| Target Validation | ||||||
| Target QSAR Model | ||||||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Histamine upregulates keratinocyte MMP-9 production via the histamine H1 receptor. J Invest Dermatol. 2008 Dec;128(12):2783-91. | |||||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7206). | |||||
| REF 3 | Emerging drugs for ocular allergy. Expert Opin Emerg Drugs. 2005 Aug;10(3):505-20. | |||||
| REF 4 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 040519. | |||||
| REF 5 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7282). | |||||
| REF 6 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 089013. | |||||
| REF 7 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7171). | |||||
| REF 8 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 040167. | |||||
| REF 9 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7466). | |||||
| REF 10 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7165). | |||||
| REF 11 | Drug information of Diphenylpyraline, 2008. eduDrugs. | |||||
| REF 12 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7132). | |||||
| REF 13 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 009319. | |||||
| REF 14 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||||
| REF 15 | Prescription and safety of dimethindene maleate micropellet capsules in Hungary. Orv Hetil. 2004 Feb 15;145(7):327-9. | |||||
| REF 16 | Drug information of Aceprometazine, 2008. eduDrugs. | |||||
| REF 17 | Comparative tolerability of second generation antihistamines. Drug Saf. 1999 May;20(5):385-401. | |||||
| REF 18 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7587). | |||||
| REF 19 | Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. | |||||
| REF 20 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7116). | |||||
| REF 21 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 018746. | |||||
| REF 22 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7119). | |||||
| REF 23 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 017601. | |||||
| REF 24 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7121). | |||||
| REF 25 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7133). | |||||
| REF 26 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 083821. | |||||
| REF 27 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7134). | |||||
| REF 28 | Drug information of Buclizine, 2008. eduDrugs. | |||||
| REF 29 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1222). | |||||
| REF 30 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6976). | |||||
| REF 31 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 070797. | |||||
| REF 32 | Drug information of Cinnarizine, 2008. eduDrugs. | |||||
| REF 33 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6063). | |||||
| REF 34 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 073283. | |||||
| REF 35 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7151). | |||||
| REF 36 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 009495. | |||||
| REF 37 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7157). | |||||
| REF 38 | Desloratadine treatment for intermittent and persistent allergic rhinitis: a review. Clin Ther. 2007 Sep;29(9):1795-802. | |||||
| REF 39 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7588). | |||||
| REF 40 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 089116. | |||||
| REF 41 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1225). | |||||
| REF 42 | Emerging treatments for depression. Expert Opin Pharmacother. 2006 Dec;7(17):2323-39. | |||||
| REF 43 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7174). | |||||
| REF 44 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7176). | |||||
| REF 45 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1247). | |||||
| REF 46 | Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol. 2001 Mar;59(3):420-6. | |||||
| REF 47 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7181). | |||||
| REF 48 | Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42. | |||||
| REF 49 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4819). | |||||
| REF 50 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7199). | |||||
| REF 51 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 085551. | |||||
| REF 52 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1586). | |||||
| REF 53 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1214). | |||||
| REF 54 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 022064. | |||||
| REF 55 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7216). | |||||
| REF 56 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1220). | |||||
| REF 57 | Antinociception induced by central administration of histamine in the formalin test in rats. Indian J Physiol Pharmacol. 2008 Jul-Sep;52(3):249-54. | |||||
| REF 58 | Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79. | |||||
| REF 59 | Inhibition by histamine H1 receptor antagonists of endogenous glibenclamide-sensitive K+ channels in follicle-enclosed Xenopus oocytes. Eur J Pharmacol. 1994 Jan 1;266(1):99-102. | |||||
| REF 60 | Drug information of Mequitazine, 2008. eduDrugs. | |||||
| REF 61 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7231). | |||||
| REF 62 | Drug information of Methdilazine, 2008. eduDrugs. | |||||
| REF 63 | Population pharmacokinetic analysis and optimization of the experimental design for mizolastine solution in children. J Pharmacokinet Pharmacodyn. 2001 Jun;28(3):299-319. | |||||
| REF 64 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7249). | |||||
| REF 65 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7329). | |||||
| REF 66 | Drug information of Phenindamine, 2008. eduDrugs. | |||||
| REF 67 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7267). | |||||
| REF 68 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7284). | |||||
| REF 69 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 012382. | |||||
| REF 70 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6326). | |||||
| REF 71 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7237). | |||||
| REF 72 | Drug information of Trimeprazine, 2008. eduDrugs. | |||||
| REF 73 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1228). | |||||
| REF 74 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||||
| REF 75 | ClinicalTrials.gov (NCT02132169) A Multi-Center Study Evaluating the Safety of AC-170 0.24%. U.S. National Institutes of Health. | |||||
| REF 76 | Population pharmacokinetics of epinastine, a histamine H1 receptor antagonist, in adults and children. Br J Clin Pharmacol. 2005 Jan;59(1):43-53. | |||||
| REF 77 | ClinicalTrials.gov (NCT00784875) An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia. U.S. National Institutes of Health. | |||||
| REF 78 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001178) | |||||
| REF 79 | ClinicalTrials.gov (NCT00409305) The Effect of Betahistine on Body Weight in Obese Subjects. U.S. National Institutes of Health. | |||||
| REF 80 | ClinicalTrials.gov (NCT01490086) RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder. U.S. National Institutes of Health. | |||||
| REF 81 | Clinical pipeline report, company report or official report of UCB. | |||||
| REF 82 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020866) | |||||
| REF 83 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2603). | |||||
| REF 84 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2608). | |||||
| REF 85 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028154) | |||||
| REF 86 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005369) | |||||
| REF 87 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000086) | |||||
| REF 88 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014046) | |||||
| REF 89 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026836) | |||||
| REF 90 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025772) | |||||
| REF 91 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028155) | |||||
| REF 92 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007218) | |||||
| REF 93 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001341) | |||||
| REF 94 | Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. | |||||
| REF 95 | Clinical pharmacology of new histamine H1 receptor antagonists. Clin Pharmacokinet. 1999 May;36(5):329-52. | |||||
| REF 96 | Nonsedating histamine H1-receptor antagonists. Clin Pharm. 1989 May;8(5):331-44. | |||||
| REF 97 | Histamine and the convulsive threshold or effectiveness of antiepileptic drugs. Przegl Lek. 2008;65(11):803-6. | |||||
| REF 98 | Influence of antazoline and ketotifen on the anticonvulsant activity of conventional antiepileptics against maximal electroshock in mice. Eur Neuropsychopharmacol. 2004 Aug;14(4):307-18. | |||||
| REF 99 | A current appreciation of sites for pharmacological intervention in allergic conjunctivitis: effects of new topical ocular drugs. Acta Ophthalmol Scand Suppl. 1999;(228):33-7. | |||||
| REF 100 | Comparative effects of loratadine and azatadine in the treatment of seasonal allergic rhinitis. Asian Pac J Allergy Immunol. 1990 Dec;8(2):103-7. | |||||
| REF 101 | The in vivo potency and selectivity of azelastine as an H1 histamine-receptor antagonist in human airways and skin. J Allergy Clin Immunol. 1988 Dec;82(6):1113-8. | |||||
| REF 102 | Histamine-induced venodilation in human beings involves both H1 and H2 receptor subtypes. J Allergy Clin Immunol. 1994 Mar;93(3):606-14. | |||||
| REF 103 | Toxicologic and clinical appraisal of buclizine, a new antihistaminic compound. J Allergy. 1956 Jan;27(1):63-7. | |||||
| REF 104 | Comparison of the effects of eleven histamine H1-receptor antagonists on monoamine turnover in the mouse brain. Naunyn Schmiedebergs Arch Pharmacol. 1994 Feb;349(2):140-4. | |||||
| REF 105 | Design, synthesis and histamine H1-receptor antagonistic activity of some novel 4-amino-2-(substituted)-5-(substituted) aryl-6-[(substituted aryl) amino] pyrimidines. Arzneimittelforschung. 2009;59(5):243-7. | |||||
| REF 106 | Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51. | |||||
| REF 107 | Identification and differentiation of alkylamine antihistamines and their metabolites in urine by computerized gas chromatography-mass spectrometry. J Chromatogr. 1988 Aug 19;430(1):31-41. | |||||
| REF 108 | Combined histamine H1 and H3 receptor blockade produces nasal decongestion in an experimental model of nasal congestion. Am J Rhinol. 1999 Sep-Oct;13(5):391-9. | |||||
| REF 109 | Central effects of cinnarizine: restricted use in aircrew. Aviat Space Environ Med. 2002 Jun;73(6):570-4. | |||||
| REF 110 | Effects of calcium-antagonistic drugs on the stimulation by carbamoylcholine and histamine of phosphatidylinositol turnover in longitudinal smooth muscle of guinea-pig ileum. Biochem J. 1976 Nov 15;160(2):163-9. | |||||
| REF 111 | Stereoselective synthesis of (-)-hydroxyclemastine as a versatile intermediate for the H1 receptor antagonist clemastine. Arch Pharm Res. 2007 Dec;30(12):1521-5. | |||||
| REF 112 | Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol. Ther Drug Monit. 2003 Apr;25(2):192-6. | |||||
| REF 113 | Comparison of cyclizine and ondansetron for the prevention of postoperative nausea and vomiting in laparoscopic day-case gynaecological surgery. Anaesthesia. 2002 Jan;57(1):61-5. | |||||
| REF 114 | Synthesis and combined H1-/H2 antagonist activity of mepyramine, pheniramine and cyclizine derivatives with cyanoguanidine, urea and nitroethenediamine partial structures. Arch Pharm (Weinheim). 1994Jul;327(7):455-62. | |||||
| REF 115 | Cyproheptadine displays preclinical activity in myeloma and leukemia. Blood. 2008 Aug 1;112(3):760-9. | |||||
| REF 116 | Antihistamines in the treatment of dermatitis. J Cutan Med Surg. 2003 Nov-Dec;7(6):467-73. | |||||
| REF 117 | Examining the tolerability of the non-sedating antihistamine desloratadine: a prescription-event monitoring study in England. Drug Saf. 2009;32(2):169-79. | |||||
| REF 118 | Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy. Curr Allergy Asthma Rep. 2009 Mar;9(2):140-8. | |||||
| REF 119 | H2 histaminergic control of inhibition of eating induced by intragastric NaCl in rats. Physiol Behav. 1998 Aug;65(1):105-13. | |||||
| REF 120 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||||
| REF 121 | Analytical method for simultaneously measuring ex vivo drug receptor occupancy and dissociation rate: application to (R)-dimethindene occupancy of central histamine H1 receptors. J Recept Signal Transduct Res. 2009;29(2):84-93. | |||||
| REF 122 | Effects of dimethindene maleate nasal spray on the quality of life in seasonal allergic rhinitis. Rhinology. 2003 Sep;41(3):159-66. | |||||
| REF 123 | Histamine as an autocrine regulator of leukemic cell proliferation. Leuk Lymphoma. 2000 Jan;36(3-4):367-73. | |||||
| REF 124 | Novel therapeutic usage of low-dose doxepin hydrochloride. Expert Opin Investig Drugs. 2007 Aug;16(8):1295-305. | |||||
| REF 125 | Evaluation of in vivo selective binding of [11C]doxepin to histamine H1 receptors in five animal species. Nucl Med Biol. 2004 May;31(4):493-502. | |||||
| REF 126 | Emedastine difumarate: a review of its potential ameliorating effect for tissue remodeling in allergic diseases. Expert Opin Pharmacother. 2009 Aug;10(11):1859-67. | |||||
| REF 127 | Influence of epinastine hydrochloride, an H1-receptor antagonist, on the function of mite allergen-pulsed murine bone marrow-derived dendritic cell... Mediators Inflamm. 2009;2009:738038. | |||||
| REF 128 | Hydroxyzine, a first generation H(1)-receptor antagonist, inhibits human ether-a-go-go-related gene (HERG) current and causes syncope in a patient ... J Pharmacol Sci. 2008 Dec;108(4):462-71. | |||||
| REF 129 | Physicochemical, pharmacological and pharmacokinetic properties of the zwitterionic antihistamines cetirizine and levocetirizine. Curr Med Chem. 2008;15(21):2173-91. | |||||
| REF 130 | Contribution of alpha4beta1 integrin to the antiallergic effect of levocabastine. Biochem Pharmacol. 2008 Sep 15;76(6):751-62. | |||||
| REF 131 | Effects of fexofenadine and other antihistamines on components of the allergic response: adhesion molecules. J Allergy Clin Immunol. 2003 Oct;112(4 Suppl):S78-82. | |||||
| REF 132 | Influence of chronic treatment with H1 receptor antagonists on the anticonvulsant activity of antiepileptic drugs. Pol J Pharmacol. 2001 Jan-Feb;53(1):93-6. | |||||
| REF 133 | Clinical research of Ibudilast on treating the steroid resistant allergic rhinitis. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009 Jan;23(2):63-6. | |||||
| REF 134 | Second-generation antihistamines: a comparative review. Drugs. 1999 Jan;57(1):31-47. | |||||
| REF 135 | Effect of descarboethoxyloratadine, the major metabolite of loratadine, on the human cardiac potassium channel Kv1.5. Br J Pharmacol. 1997 Nov;122(5):796-8. | |||||
| REF 136 | Receptor mediation and nociceptin inhibition of bradykinin-induced plasma extravasation in the knee joint of the rat. Inflamm Res. 2009 Dec;58(12):873-80. | |||||
| REF 137 | Efficiency of mequitazine in the treatment of allergic rhinitis and chronic urticaria in children. A bibliographic systematic review. Rev Alerg Mex. 2008 Jan-Feb;55(1):3-9. | |||||
| REF 138 | Effect of H1 blockers alone and in combination with morphine to produce antinociception in mice. Neuropharmacology. 1985 Jan;24(1):1-4. | |||||
| REF 139 | Histamine H1-receptor antagonists inhibit nuclear factor-kappaB and activator protein-1 activities via H1-receptor-dependent and -independent mechanisms. Clin Exp Allergy. 2008 Jun;38(6):947-56. | |||||
| REF 140 | The effect of a combined therapy with a histamine H1 antagonist and a chemical mediator release inhibitor on allergic conjunctivitis. Ophthalmologica. 2008;222(4):232-9. | |||||
| REF 141 | The histamine H1-receptor antagonist binding site. A stereoselective pharmacophoric model based upon (semi-)rigid H1-antagonists and including a known interaction site on the receptor. J Med Chem. 1995 Aug 18;38(17):3351-60. | |||||
| REF 142 | Role of central histaminergic system in lorazepam withdrawal syndrome in rats. Pharmacol Biochem Behav. 2001 Apr;68(4):777-82. | |||||
| REF 143 | How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. | |||||
| REF 144 | Effectiveness of alimemazine in controlling retching after Nissen fundoplication. J Pediatr Surg. 2005 Nov;40(11):1737-40. | |||||
| REF 145 | Involvement of histamine H1 and H2 receptors in the regulation of STAT-1 phosphorylation: inverse agonism exhibited by the receptor antagonists. Int Immunopharmacol. 2005 Jul;5(7-8):1299-309. | |||||
| REF 146 | Role of N-methyl-D-aspartate receptors in gastric mucosal blood flow induced by histamine. J Neurosci Res. 2004 Sep 1;77(5):730-8. | |||||
| REF 147 | Prostaglandin E2 aggravates gastric mucosal injury induced by histamine in rats through EP1 receptors. Life Sci. 2003 Dec 19;74(5):629-41. | |||||
| REF 148 | Histamine H1 and H2 receptor antagonists accelerate skin barrier repair and prevent epidermal hyperplasia induced by barrier disruption in a dry environment. J Invest Dermatol. 2001 Feb;116(2):261-5. | |||||
| REF 149 | Histamine excites rat lateral vestibular nuclear neurons through activation of post-synaptic H2 receptors. Neurosci Lett. 2008 Dec 19;448(1):15-9. | |||||
| REF 150 | Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43. | |||||
| REF 151 | Clinical pipeline report, company report or official report of NicOx SA. | |||||
| REF 152 | Current Phase II investigational therapies for insomnia. Expert Opin Investig Drugs. 2015 Mar;24(3):401-11. | |||||
| REF 153 | A double-blind placebo controlled dose response study of noberastine on histamine induced weal and flare. Eur J Clin Pharmacol. 1991;40(1):83-5. | |||||
| REF 154 | Betahistine in the treatment of M ni re's disease. Neuropsychiatr Dis Treat. 2007 August; 3(4): 429-440. | |||||
| REF 155 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
| REF 156 | The effect of a novel, dual function histamine H1 receptor antagonist/5-lipoxygenase enzyme inhibitor on in vivo dermal inflammation and extravasat... Eur J Pharmacol. 2005 Jan 4;506(3):265-71. | |||||
| REF 157 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020866) | |||||
| REF 158 | Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. | |||||
| REF 159 | Small mouse cholangiocytes proliferate in response to H1 histamine receptor stimulation by activation of the IP3/CaMK I/CREB pathway. Am J Physiol Cell Physiol. 2008 Aug;295(2):C499-513. | |||||
| REF 160 | Effect of tecastemizole on pulmonary and cutaneous allergic inflammatory responses. Clin Exp Allergy. 2007 Jun;37(6):909-17. | |||||
| REF 161 | Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). | |||||
| REF 162 | Studies on the novel antiallergic agent HSR-609: its penetration into the central nervous system in mice and guinea pigs and its selectivity for the histamine H1-receptor. Jpn J Pharmacol. 1997 Apr;73(4):291-8. | |||||
| REF 163 | High-affinity binding of mequitamium iodide (LG 30435) to muscarinic and histamine H1 receptors. Eur J Pharmacol. 1990 Jul 17;182(3):413-20. | |||||
| REF 164 | ReN 1869, a novel tricyclic antihistamine, is active against neurogenic pain and inflammation. Eur J Pharmacol. 2002 Jan 18;435(1):43-57. | |||||
| REF 165 | Preclinical efficacy and safety pharmacology of SUN-1334H, a potent orally active antihistamine agent. Drugs R D. 2008;9(2):93-112. | |||||
| REF 166 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | |||||
| REF 167 | Effect of BN 52256 and other mediator antagonists on ouabain-induced cardiac arrhythmia in a model of anaphylaxis in guinea-pigs. Pharmacol Res. 1992 Feb-Mar;25(2):173-80. | |||||
| REF 168 | A novel phenylaminotetralin radioligand reveals a subpopulation of histamine H(1) receptors. J Pharmacol Exp Ther. 2002 Jul;302(1):328-36. | |||||
| REF 169 | Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs. Bioorg Med Chem Lett. 2009 Sep 1;19(17):5043-7. | |||||
| REF 170 | Stereoselective synthesis of desloratadine derivatives as antagonist of histamine. Bioorg Med Chem. 2010 Feb 15;18(4):1626-32. | |||||
| REF 171 | Multiple differences in agonist and antagonist pharmacology between human and guinea pig histamine H1-receptor. J Pharmacol Exp Ther. 2003 Jun;305(3):1104-15. | |||||
| REF 172 | Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. Bioorg Med Chem. 2009 Sep 15;17(18):6496-504. | |||||
| REF 173 | Large-scale overproduction, functional purification and ligand affinities of the His-tagged human histamine H1 receptor. Eur J Biochem. 2004 Jul;271(13):2636-46. | |||||
| REF 174 | Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. | |||||
| REF 175 | Conformationally-restricted ligands for the histamine H1 receptor. Bioorg Med Chem Lett. 2000 Jun 5;10(11):1277-9. | |||||
| REF 176 | Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles. Bioorg Med Chem Lett. 2010 Jan 1;20(1):78-82. | |||||
| REF 177 | Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first pote... J Pharmacol Exp Ther. 2005 Sep;314(3):1310-21. | |||||
| REF 178 | Probing ligand-specific histamine H1- and H2-receptor conformations with NG-acylated Imidazolylpropylguanidines. J Pharmacol Exp Ther. 2006 Apr;317(1):139-46. | |||||
| REF 179 | Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum. Antimicrob Agents Chemother. 2007 Nov;51(11):4133-40. | |||||
| REF 180 | Exploring the neuroleptic substituent in octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for (1)-adre... J Med Chem. 2010 Oct 14;53(19):7021-34. | |||||
| REF 181 | Tricyclic isoxazolines: identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and alpha2-a... Bioorg Med Chem. 2007 Jun 1;15(11):3649-60. | |||||
| REF 182 | Characterization of novel selective H1-antihistamines for clinical evaluation in the treatment of insomnia. J Med Chem. 2009 Sep 10;52(17):5307-10. | |||||
| REF 183 | Fragment based design of new H4 receptor-ligands with anti-inflammatory properties in vivo. J Med Chem. 2008 Apr 24;51(8):2457-67. | |||||
| REF 184 | Cryo-EM structure of the human histamine H(1) receptor/G(q) complex. Nat Commun. 2021 Apr 7;12(1):2086. | |||||
| REF 185 | Structure of the human histamine H1 receptor complex with doxepin. Nature. 2011 Jun 22;475(7354):65-70. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.